The intricate role of CXCR4 in cancer

Advances in Cancer Research

Volumn 124, Issue , 2014, Pages 31-82

  Chatterjee, Samit ^a   Behnam Azad, Babak ^a   Nimmagadda, Sridhar ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer therapy; Chemokine receptor; Chemotaxis; CXCL12; CXCR4 inhibitor; CXCR4 tracers; Metastasis; Molecular imaging; PET CT; Therapeutic intervention

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CISPLATIN; CYCLOPEPTIDE; MONOCLONAL ANTIBODY; PEPTIDOMIMETIC AGENT; STROMAL CELL DERIVED FACTOR 1; SYNTHETIC PEPTIDE;

ARTICLE; BRAIN TUMOR; BREAST CANCER; DIGESTIVE SYSTEM CANCER; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGY; PROSTATE CANCER; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOMATIC MUTATION; ANIMAL; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; MOLECULAR IMAGING; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR IMAGING; NEOPLASMS; RECEPTORS, CXCR4;

EID: 84907816979     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/B978-0-12-411638-2.00002-1     Document Type: Chapter

References (296)

1. ACS Cancer facts and figures 2014 2014, American Cancer Society, Atlanta, GA.
2. Ahr B., Denizot M., Robert-Hebmann V., Brelot A., Biard-Piechaczyk M. Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation. Journal of Biological Chemistry 2005, 280(8):6692-6700.
3. Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. Journal of Experimental Medicine 1997, 185(1):111-120.
4. Akashi T., Koizumi K., Tsuneyama K., Saiki I., Takano Y., Fuse H. Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Science 2008, 99(3):539-542.
5. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U.K., Pitsillides C.M., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 2007, 109(7):2708-2717.
6. Baccelli I., Trumpp A. The evolving concept of cancer and metastasis stem cells. Journal of Cell Biology 2012, 198(3):281-293.
7. Bachelerie F. CXCL12/CXCR4-axis dysfunctions: Markers of the rare immunodeficiency disorder WHIM syndrome. Disease Markers 2010, 29(3-4):189-198.
8. Bachet J.B., Marechal R., Demetter P., Bonnetain F., Couvelard A., Svrcek M., et al. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Annals of Oncology 2012, 23(9):2327-2335.
9. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998, 392(6676):565-568.
10. Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B., et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. Journal of Biological Chemistry 2005, 280(42):35760-35766.
11. Balkwill F. Cancer and the chemokine network. Nature Reviews. Cancer 2004, 4(7):540-550.
12. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Seminars in Cancer Biology 2004, 14(3):171-179.
13. Bao L., Lai Y., Liu Y., Qin Y., Zhao X., Lu X., et al. CXCR4 is a good survival prognostic indicator in multiple myeloma patients. Leukemia Research 2013, 37(9):1083-1088.
14. Barbolina M.V., Kim M., Liu Y., Shepard J., Belmadani A., Miller R.J., et al. Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Molecular Cancer Research 2010, 8(5):653-664.
15. Baribaud F., Edwards T.G., Sharron M., Brelot A., Heveker N., Price K., et al. Antigenically distinct conformations of CXCR4. Journal of Virology 2001, 75(19):8957-8967.
16. Barretina J., Junca J., Llano A., Gutierrez A., Flores A., Blanco J., et al. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Annals of Hematology 2003, 82(8):500-505.
17. Bartolome R.A., Ferreiro S., Miquilena-Colina M.E., Martinez-Prats L., Soto-Montenegro M.L., Garcia-Bernal D., et al. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. American Journal of Pathology 2009, 174(2):602-612.
18. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nature Reviews. Cancer 2008, 8(7):545-554.
19. Beider K., Begin M., Abraham M., Wald H., Weiss I.D., Wald O., et al. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Experimental Hematology 2011, 39(3):282-292.
20. Bendall L.J., Baraz R., Juarez J., Shen W., Bradstock K.F. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer Research 2005, 65(8):3290-3298.
21. Bertolini F., Dell'Agnola C., Mancuso P., Rabascio C., Burlini A., Monestiroli S., et al. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Research 2002, 62(11):3106-3112.
22. Bertolini G., Roz L., Perego P., Tortoreto M., Fontanella E., Gatti L., et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(38):16281-16286.
23. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382(6594):829-833.
24. Bleul C.C., Fuhlbrigge R.C., Casasnovas J.M., Aiuti A., Springer T.A. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). Journal of Experimental Medicine 1996, 184(3):1101-1109.
25. Buckle T., van den Berg N.S., Kuil J., Bunschoten A., Oldenburg J., Borowsky A.D., et al. Non-invasive longitudinal imaging of tumor progression using an 111Indium labeled CXCR4 peptide antagonist. European Journal of Nuclear Medicine and Molecular Imaging 2012, 38:S145.
26. Buckley C.D., Amft N., Bradfield P.F., Pilling D., Ross E., Arenzana-Seisdedos F., et al. Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. Journal of Immunology 2000, 165(6):3423-3429.
27. Bunschoten A., Buckle T., Kuil J., Luker G.D., Luker K.E., Nieweg O.E., et al. Targeted non-covalent self-assembled nanoparticles based on human serum albumin. Biomaterials 2012, 33(3):867-875. 10.1016/j.biomaterials.2011.10.005.
28. Burger J.A. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Current Opinion in Oncology 2009, 24(6):643-649.
29. Burger J.A. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Seminars in Cancer Biology 2010, 20(6):424-430.
30. Burger J.A., Burger M., Kipps T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999, 94(11):3658-3667.
31. Burger M., Glodek A., Hartmann T., Schmitt-Graff A., Silberstein L.E., Fujii N., et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003, 22(50):8093-8101.
32. Burger J.A., Peled A. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23(1):43-52.
33. Burger J.A., Stewart D.J., Wald O., Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Review of Anticancer Therapy 2011, 11(4):621-630.
34. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. Journal of Experimental Medicine 2006, 203(9):2201-2213.
35. Cabioglu N., Summy J., Miller C., Parikh N.U., Sahin A.A., Tuzlali S., et al. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Research 2005, 15:6493-6497. 10.1158/0008-5472.CAN-04-1303.
36. Camaj P., Jackel C., Krebs S., Detoni E.N., Blum H., Jauch K.W., et al. Hypoxia-independent gene expression mediated by SOX9 promotes aggressive pancreatic tumor biology. Molecular Cancer Research 2014, 12(3):421-432.
37. CDC Cancer among men 2013.
38. Chen Y., Huang Y., Reiberger T., Duyverman A.M., Huang P., Samuel R., et al. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 2014, 59(4):1435-1447.
39. Chen Y., Jacamo R., Konopleva M., Garzon R., Croce C., Andreeff M. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. Journal of Clinical Investigation 2013, 123(6):2395-2407.
40. Chen H.Y., Wang J.M., Wang H.Y., Zhang Y.X., Liu W., Pan L., et al. Effect of short hairpin RNA-induced CXCR4 silence on ovarian cancer cell. Biomedicine & Pharmacotherapy 2012, 66(7):549-553.
41. Choi W.T., Duggineni S., Xu Y., Huang Z., An J. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). Journal of Medicinal Chemistry 2012, 55(3):977-994.
42. Chong B.F., Mohan C. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus. Expert Opinion on Therapeutic Targets 2009, 13(10):1147-1153.
43. Chu Q.D., Panu L., Holm N.T., Li B.D., Johnson L.W., Zhang S. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome. Journal of Surgical Research 2010, 159(2):689-695.
44. Chu H., Zhou H., Liu Y., Liu X., Hu Y., Zhang J. Functional expression of CXC chemokine receptor-4 mediates the secretion of matrix metalloproteinases from mouse hepatocarcinoma cell lines with different lymphatic metastasis ability. International Journal of Biochemistry & Cell Biology 2007, 39(1):197-205.
45. Chung D.T., Chang L.-W., Huang Y.-H., Tsai C.-Y., Hsu C.-H., King C.-H.R., et al. TG-0054, a novel and potent stem cell mobilizer, displays excellent PK/PD and safety profile in phase I trial. Blood 2009, 114(22):357.
46. Chung S.H., Seki K., Choi B.I., Kimura K.B., Ito A., Fujikado N., et al. CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis. Arthritis Research & Therapy 2010, 12(5):R188.
47. Collins C.D. Problems monitoring response in multiple myeloma. Cancer Imaging 2005, 5(Spec No A):S119-S126.
48. D'Alterio C., Consales C., Polimeno M., Franco R., Cindolo L., Portella L., et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Current Cancer Drug Targets 2010, 10(7):772-781.
49. Darash-Yahana M., Pikarsky E., Abramovitch R., Zeira E., Pal B., Karplus R., et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB Journal 2004, 18(11):1240-1242.
50. Debnath B., Xu S., Grande F., Garofalo A., Neamati N. Small molecule inhibitors of CXCR4. Theranostics 2013, 3(1):47-75.
51. De Clercq E. The bicyclam AMD3100 story. Nature Reviews. Drug Discovery 2003, 2(7):581-587.
52. De Clercq E. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers. Pharmacology & Therapeutics 2010, 128(3):509-518.
53. De Klerck B., Geboes L., Hatse S., Kelchtermans H., Meyvis Y., Vermeire K., et al. Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis. Arthritis Research & Therapy 2005, 7(6):R1208-R1220.
54. DeMarco S.J., Henze H., Lederer A., Moehle K., Mukherjee R., Romagnoli B., et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorganic & Medicinal Chemistry 2006, 14(24):8396-8404.
55. Demmer O., Dijkgraaf I., Schumacher U., Marinelli L., Cosconati S., Gourni E., et al. Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4. Journal of Medicinal Chemistry 2011, 54(21):7648-7662. 10.1021/jm2009716.
56. Demmer O., Gourni E., Schumacher U., Kessler H., Wester H.-J. PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem 2011, 6(10):1789-1791. 10.1002/cmdc.201100320.
57. De Silva R.A., Peyre K., Pullambhatla M., Fox J.J., Pomper M.G., Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: Evaluation of monocyclam Cu-64-AMD3465. Journal of Nuclear Medicine 2011, 52(6):986-993. 10.2967/jnumed.110.085613.
58. Devine S.M., Vij R., Rettig M., Todt L., McGlauchlen K., Fisher N., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112(4):990-998.
59. Dillmann F., Veldwijk M.R., Laufs S., Sperandio M., Calandra G., Wenz F., et al. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+cell to Imatinib and Nilotinib. Leukemia & Lymphoma 2009, 50(10):1676-1686.
60. DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N., Stiff P.J., Kaufman J.L., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113(23):5720-5726.
61. DiPersio J.F., Uy G.L., Yasothan U., Kirkpatrick P. Plerixafor. Nature Reviews. Drug Discovery 2009, 8(2):105-106.
62. Domanska U.M., Kruizinga R.C., Nagengast W.B., Timmer-Bosscha H., Huls G., de Vries E.G., et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. European Journal of Cancer 2012, 49(1):219-230.
63. Duda D.G., Kozin S.V., Kirkpatrick N.D., Xu L., Fukumura D., Jain R.K. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies?. Clinical Cancer Research 2011, 17(8):2074-2080.
64. Eck S.M., Cote A.L., Winkelman W.D., Brinckerhoff C.E. CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells. Molecular Cancer Research 2009, 7(7):1033-1044.
65. Engl T., Relja B., Marian D., Blumenberg C., Muller I., Beecken W.D., et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006, 8(4):290-301.
66. Esencay M., Newcomb E.W., Zagzag D. HGF upregulates CXCR4 expression in gliomas via NF-kappaB: Implications for glioma cell migration. Journal of Neuro-Oncology 2010, 99(1):33-40.
67. Fahham D., Weiss I.D., Abraham M., Beider K., Hanna W., Shlomai Z., et al. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery 2012, 144(5):1167-1175. e1161.
68. Fakhari S., Kalantar E., Nikzaban M., Hakhamneshi M.S., Fathi F., Nikkhoo B., et al. Effect of Helicobacter pylori infection on stromal-derived factor-1/CXCR4 axis in bone marrow-derived mesenchymal stem cells. Advanced Biomedical Research 2014, 3:19.
69. Farzan M., Babcock G.J., Vasilieva N., Wright P.L., Kiprilov E., Mirzabekov T., et al. The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry. Journal of Biological Chemistry 2002, 277(33):29484-29489.
70. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272(5263):872-877.
71. Fernandis A.Z., Cherla R.P., Chernock R.D., Ganju R.K. CXCR4/CCR5 down-modulation and chemotaxis are regulated by the proteasome pathway. Journal of Biological Chemistry 2002, 277(20):18111-18117.
72. Franco R., Pirozzi G., Scala S., Cantile M., Scognamiglio G., Camerlingo R., et al. CXCL12-binding receptors expression in non-small cell lung cancer relates to tumoral microvascular density and CXCR4 positive circulating tumoral cells in lung draining venous blood. European Journal of Cardio-Thoracic Surgery 2011, 41(2):368-375.
73. Fricker S.P., Anastassov V., Cox J., Darkes M.C., Grujic O., Idzan S.R., et al. Characterization of the molecular pharmacology of AMD3100: A specific antagonist of the G-protein coupled chemokine receptor, CXCR4. Biochemical Pharmacology 2006, 72(5):588-596.
74. Fujii N., Oishi S., Hiramatsu K., Araki T., Ueda S., Tamamura H., et al. Molecular-size reduction of a potent CXCR4-chemokine antagonist using orthogonal combination of conformation- and sequence-based libraries. Angewandte Chemie International Edition 2003, 42(28):3251-3253. 10.1002/anie.200351024.
75. Furusato B., Mohamed A., Uhlen M., Rhim J.S. CXCR4 and cancer. Pathology International 2010, 60(7):497-505.
76. Gagliardi F., Narayanan A., Reni M., Franzin A., Mazza E., Boari N., et al. The role of CXCR4 in highly malignant human gliomas biology: Current knowledge and future directions. Glia 2014, 62(7):1015-1023. 10.1002/glia.22669.
77. Gahan J.C., Gosalbez M., Yates T., Young E.E., Escudero D.O., Chi A., et al. Chemokine and chemokine receptor expression in kidney tumors: Molecular profiling of histological subtypes and association with metastasis. Journal of Urology 2012, 187(3):827-833.
78. Gambaryan N., Perros F., Montani D., Cohen-Kaminsky S., Mazmanian M., Renaud J.F., et al. Targeting of c-kit+haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. European Respiratory Journal 2011, 37(6):1392-1399.
79. Ganju R.K., Brubaker S.A., Meyer J., Dutt P., Yang Y., Qin S., et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. Journal of Biological Chemistry 1998, 273(36):23169-23175.
80. Gao Z., Wang X., Wu K., Zhao Y., Hu G. Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis. Pancreatology 2010, 10(2-3):186-193.
81. Gatti M., Pattarozzi A., Bajetto A., Wurth R., Daga A., Fiaschi P., et al. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology 2013, 314(2-3):209-220.
82. George G.P.C., Stevens E., Aberg O., Quang-De N., Pisaneschi F., Spivey A.C., et al. Preclinical evaluation of a CXCR4-specific Ga-68-labelled TN14003 derivative for cancer PET imaging. Bioorganic & Medicinal Chemistry 2014, 22(2):796-803. 10.1016/j.bmc.2013.12.012.
83. Gilman A.G. G proteins: Transducers of receptor-generated signals. Annual Review of Biochemistry 1987, 56:615-649.
84. Gladson C.L., Welch D.R. New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biology & Therapy 2008, 7(11):1849-1851.
85. Gockel I., Schimanski C.C., Heinrich C., Wehler T., Frerichs K., Drescher D., et al. Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. BMC Cancer 2006, 6:290.
86. Goldsmith Z.G., Dhanasekaran D.N. G protein regulation of MAPK networks. Oncogene 2007, 26(22):3122-3142.
87. Gulino A.V. WHIM syndrome: A genetic disorder of leukocyte trafficking. Current Opinion in Allergy and Clinical Immunology 2003, 3(6):443-450.
88. Gupta S.K., Lysko P.G., Pillarisetti K., Ohlstein E., Stadel J.M. Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines. Journal of Biological Chemistry 1998, 273(7):4282-4287.
89. Han M., Lv S., Zhang Y., Yi R., Huang B., Fu H., et al. The prognosis and clinicopathology of CXCR4 in gastric cancer patients: A meta-analysis. Tumour Biology 2014, 35(5):4589-4597.
90. Han S., Ritzenthaler J.D., Sitaraman S.V., Roman J. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-Fos via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. Journal of Biological Chemistry 2006, 281(40):29614-29624.
91. Hartimath S.V., Domanska U.M., Walenkamp A.M.E., Dierckx R.A.J.O., de Vries E.F.J. [Tc-99m]O-2-AMD3100 as a SPECT tracer for CXCR4 receptor imaging. Nuclear Medicine and Biology 2013, 40(4):507-517. 10.1016/j.nucmedbio.2013.02.003.
92. Hassan S., Ferrario C., Saragovi U., Quenneville L., Gaboury L., Baccarelli A., et al. The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. The American Journal of Pathology 2009, 175(1):66-73. 10.2353/ajpath.2009.080948.
93. Hatse S., Princen K., Bridger G., De Clercq E., Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Letters 2002, 527(1-3):255-262.
94. Hattermann K., Mentlein R. An infernal trio: The chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Annals of Anatomy 2013, 195(2):103-110.
95. He J., Chen Y., Farzan M., Choe H., Ohagen A., Gartner S., et al. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997, 385(6617):645-649.
96. Heesen M., Berman M.A., Benson J.D., Gerard C., Dorf M.E. Cloning of the mouse fusin gene, homologue to a human HIV-1 co-factor. Journal of Immunology 1996, 157(12):5455-5460.
97. Hendrix C.W., Collier A.C., Lederman M.M., Schols D., Pollard R.B., Brown S., et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes 2004, 37(2):1253-1262.
98. Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrobial Agents and Chemotherapy 2000, 44(6):1667-1673.
99. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1(3):313-323.
100. Hernandez P.A., Gorlin R.J., Lukens J.N., Taniuchi S., Bohinjec J., Francois F., et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nature Genetics 2003, 34(1):70-74.
101. Hesselgesser J., Halks-Miller M., DelVecchio V., Peiper S.C., Hoxie J., Kolson D.L., et al. CD4-independent association between HIV-1 gp120 and CXCR4: Functional chemokine receptors are expressed in human neurons. Current Biology 1997, 7(2):112-121.
102. Ho T.K., Shiwen X., Abraham D., Tsui J., Baker D. Stromal-cell-derived factor-1 (SDF-1)/CXCL12 as potential target of therapeutic angiogenesis in critical leg ischaemia. Cardiology Research and Practice 2012, 2012:143209.
103. Hoffmann F., Muller W., Schutz D., Penfold M.E., Wong Y.H., Schulz S., et al. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues. Journal of Biological Chemistry 2012, 287(34):28362-28377.
104. Holm N.T., Byrnes K., Li B.D., Turnage R.H., Abreo F., Mathis J.M., et al. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. Journal of Surgical Research 2007, 141(1):53-59.
105. Howard O.M., Ben-Baruch A., Oppenheim J.J. Chemokines: Progress toward identifying molecular targets for therapeutic agents. Trends in Biotechnology 1996, 14(2):46-51.
106. Hsu W., Rosenquist G.L., Ansari A.A., Gershwin M.E. Autoimmunity and tyrosine sulfation. Autoimmunity Reviews 2005, 4(7):429-435.
107. Huang E.H., Singh B., Cristofanilli M., Gelovani J., Wei C., Vincent L., et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. Journal of Surgical Research 2009, 155(2):231-236.
108. Hubbard M.O., Fu P., Margevicius S., Dowlati A., Linden P.A. Five-year survival does not equal cure in non-small cell lung cancer: A surveillance, epidemiology, and end results-based analysis of variables affecting 10- to 18-year survival. Journal of Thoracic and Cardiovascular Surgery 2012, 143(6):1307-1313.
109. Hunter Z.R., Xu L., Yang G., Zhou Y., Liu X., Cao Y., et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2012, 123(11):1637-1646.
110. Ishikawa T., Nakashiro K., Klosek S.K., Goda H., Hara S., Uchida D., et al. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncology Reports 2009, 21(3):707-712.
111. Iwanaga T., Iwasaki Y., Ohashi M., Nunobe S., Iwagami S. Establishment of a CXCR4-expressing gastric cancer cell line in nude mice and the effect of AMD 3100 on tumor regression. Gan to Kagaku Ryoho 2007, 34(12):1917-1919.
112. Iwanaga T., Iwasaki Y., Ohashi M., Ohinata R., Takahashi K., Yamaguchi T., et al. Inhibitory effect of CXCR4 blockers on a CXCR4-expressing gastric cancer cell line in nude mice. Gan to Kagaku Ryoho 2012, 39(12):1788-1790.
113. Jacobson O., Weiss I.D., Kiesewetter D.O., Farber J.M., Chen X. PET of tumor CXCR4 expression with 4-F-18-T140. Journal of Nuclear Medicine 2010, 51(11):1796-1804. 10.2967/jnumed.110.079418.
114. Jacobson O., Weiss I.D., Szajek L., Farber J.M., Kiesewetter D.O. Cu-64-AMD3100-A novel imaging agent for targeting chemokine receptor CXCR4. Bioorganic & Medicinal Chemistry 2009, 17(4):1486-1493. 10.1016/j.bmc.2009.01.014.
115. Jacobson O., Weiss I.D., Szajek L.P., Niu G., Ma Y., Kiesewetter D.O., et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics 2011, 1:251-262. 10.7150/thno/v01p0251.
116. Jacobson O., Weiss I.D., Szajek L.P., Niu G., Ma Y., Kiesewetter D.O., et al. Improvement of CXCR4 tracer specificity for PET imaging. Journal of Controlled Release 2012, 157(2):216-223. 10.1016/j.jconrel.2011.09.076.
117. Janowski M. Functional diversity of SDF-1 splicing variants. Cell Adhesion & Migration 2009, 3(3):243-249.
118. Jerant A.F., Johnson J.T., Sheridan C.D., Caffrey T.J. Early detection and treatment of skin cancer. American Family Physician 2000, 62(2):357-368. 375-356, 381-352.
119. Jiang Y.P., Wu X.H., Shi B., Wu W.X., Yin G.R. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecologic Oncology 2006, 103(1):226-233.
120. Jung M.J., Rho J.K., Kim Y.M., Jung J.E., Jin Y.B., Ko Y.G., et al. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 2013, 32(2):209-221.
121. Kajiyama H., Shibata K., Terauchi M., Ino K., Nawa A., Kikkawa F. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. International Journal of Cancer 2008, 122(1):91-99.
122. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3(6):537-549.
123. Kang H., Watkins G., Douglas-Jones A., Mansel R.E., Jiang W.G. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 2005, 14(5):360-367.
124. Kato M., Kitayama J., Kazama S., Nagawa H. Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Research 2003, 5(5):R144-R150. 10.1186/bcr627.
125. Kim M., Koh Y.J., Kim K.E., Koh B.I., Nam D.H., Alitalo K., et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Research 2010, 70(24):10411-10421.
126. Kim S.Y., Lee C.H., Midura B.V., Yeung C., Mendoza A., Hong S.H., et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clinical & Experimental Metastasis 2008, 25(3):201-211.
127. Kim J., Mori T., Chen S.L., Amersi F.F., Martinez S.R., Kuo C., et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Annals of Surgery 2006, 244(1):113-120.
128. Kim J., Takeuchi H., Lam S.T., Turner R.R., Wang H.J., Kuo C., et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. Journal of Clinical Oncology 2005, 23(12):2744-2753.
129. Ko S.Y., Park C.J., Park S.H., Cho Y.U., Jang S., Seo E.J., et al. High CXCR4 and low VLA-4 expression predicts poor survival in adults with acute lymphoblastic leukemia. Leukemia Research 2014, 38(1):65-70.
130. Kojima Y., Acar A., Eaton E.N., Mellody K.T., Scheel C., Ben-Porath I., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(46):20009-20014.
131. Konoplev S., Jorgensen J.L., Thomas D.A., Lin E., Burger J., Kantarjian H.M., et al. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer 2011, 117(20):4689-4695.
132. Konopleva M.Y., Jordan C.T. Leukemia stem cells and microenvironment: Biology and therapeutic targeting. Journal of Clinical Oncology 2011, 29(5):591-599.
133. Kryczek I., Wei S., Keller E., Liu R., Zou W. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. American Journal of Physiology. Cell Physiology 2007, 292(3):C987-C995. 10.1152/ajpcell.00406.2006.
134. Kucia M., Jankowski K., Reca R., Wysoczynski M., Bandura L., Allendorf D.J., et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. Journal of Molecular Histology 2004, 35(3):233-245.
135. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23(7):879-894.
136. Kuhne M.R., Mulvey T., Belanger B., Chen S., Pan C., Chong C., et al. BMS-936564/MDX-1338: A fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clinical Cancer Research 2012, 19(2):357-366.
137. Kuil J., Buckle T., Oldenburg J., Yuan H., Borowsky A.D., Josephson L., et al. Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression. Molecular Pharmaceutics 2011, 8(6):2444-2453. 10.1021/mp200401p.
138. Kuil J., Buckle T., Yuan H., van den Berg N.S., Oishi S., Fujii N., et al. Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide. Bioconjugate Chemistry 2011, 22(5):859-864. 10.1021/bc2000947.
139. Kukreja P., Abdel-Mageed A.B., Mondal D., Liu K., Agrawal K.C. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: Role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Research 2005, 65(21):9891-9898.
140. Kwong J., Kulbe H., Wong D., Chakravarty P., Balkwill F. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Molecular Cancer Therapeutics 2009, 8(7):1893-1905.
141. Lanza F., Lemoli R.M., Olivieri A., Laszlo D., Martino M., Specchia G., et al. Factors affecting successful mobilization with plerixafor: An Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion 2014, 54(2):331-339.
142. Lazarini F., Tham T.N., Casanova P., Arenzana-Seisdedos F., Dubois-Dalcq M. Role of the alpha-chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia 2003, 42(2):139-148.
143. Le Y., Zhou Y., Iribarren P., Wang J. Chemokines and chemokine receptors: Their manifold roles in homeostasis and disease. Cellular and Molecular Immunology 2004, 1(2):95-104.
144. Lederer A., DeMarco S.J., Henze H., Romagnoli B., Mukherjee R., Zumbrunn J., et al. Discovery of highly potent and selective CXCR4 inhibitors using protein epitope mimetics (PEM) technology. Chimia 2007, 61(4):147-150.
145. Li G., Badin G., Zhao A., Gentil-Perret A., Tostain J., Peoc'h M., et al. Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma. Histology and Histopathology 2013, 28(9):1217-1222.
146. Li W., Gomez E., Zhang Z. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 2007, 26(4):527-533.
147. Li C.X., Wu D.P., Wang Y.D., Yu G.H., Liu J.M., Zhuang Y.M., et al. Expression of CXCR4 and its effect on the biological behavior of multiple myeloma cells. Zhonghua Xue Ye Xue Za Zhi 2003, 24(3):122-125.
148. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Research 2005, 65(3):967-971.
149. Liang Z., Zhan W., Zhu A., Yoon Y., Lin S., Sasaki M., et al. Development of a unique small molecule modulator of CXCR4. PLoS One 2012, 7(4):e34038.
150. Liao Y.X., Zhou C.H., Zeng H., Zuo D.Q., Wang Z.Y., Yin F., et al. The role of the CXCR4/CXCL12/CXCR7 axis in the progression and metastasis of bone sarcomas (Review). International Journal of Molecular Medicine 2013, 32(6):1239-1246.
151. Liles W.C., Broxmeyer H.E., Rodger E., Wood B., Hubel K., Cooper S., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102(8):2728-2730.
152. Ling X., Spaeth E., Chen Y., Shi Y., Zhang W., Schober W., et al. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One 2013, 8(3):e58426.
153. Liu C.F., Liu S.Y., Min X.Y., Ji Y.Y., Wang N., Liu D., et al. The prognostic value of CXCR4 in ovarian cancer: A meta-analysis. PLoS One 2014, 9(3):e92629.
154. Liu Y., Wang B., Wang J., Wan W., Sun R., Zhao Y., et al. Down-regulation of PKCzeta expression inhibits chemotaxis signal transduction in human lung cancer cells. Lung Cancer 2009, 63(2):210-218.
155. Longo-Imedio M.I., Longo N., Trevino I., Lazaro P., Sanchez-Mateos P. Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. International Journal of Cancer 2005, 117(5):861-865.
156. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2095-2128.
157. Ma Y., Hwang R.F., Logsdon C.D., Ullrich S.E. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Research 2013, 73(13):3927-3937.
158. Ma Q., Jones D., Borghesani P.R., Segal R.A., Nagasawa T., Kishimoto T., et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(16):9448-9453.
159. Marechal R., Demetter P., Nagy N., Berton A., Decaestecker C., Polus M., et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. British Journal of Cancer 2009, 100(9):1444-1451.
160. Masuda M., Nakashima H., Ueda T., Naba H., Ikoma R., Otaka A., et al. A novel anti-hiv synthetic peptide, T-22 ([Tyr5,12, Lys7]-polyphemusin-II). Biochemical and Biophysical Research Communications 1992, 189(2):845-850. 10.1016/0006-291x(92)92280-b.
161. Mavier P., Martin N., Couchie D., Preaux A.M., Laperche Y., Zafrani E.S. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. American Journal of Pathology 2004, 165(6):1969-1977.
162. McDermott D.H., Liu Q., Velez D., Lopez L., Anaya-O'Brien S., Ulrick J., et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood 2014, 123(15):2308-2316.
163. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clinical Cancer Research 2008, 14(9):2519-2526.
164. Meincke M., Tiwari S., Hattermann K., Kalthoff H., Mentlein R. Near-infrared molecular imaging of tumors via chemokine receptors CXCR4 and CXCR7. Clinical & Experimental Metastasis 2011, 28(8):713-720. 10.1007/s10585-011-9403-y.
165. Mellado M., Rodriguez-Frade J.M., Manes S., Martinez A.C. Chemokine signaling and functional responses: The role of receptor dimerization and TK pathway activation. Annual Review of Immunology 2001, 19:397-421.
166. Misra P., Lebeche D., Ly H., Schwarzkopf M., Diaz G., Hajjar R.J., et al. Quantitation of CXCR4 expression in myocardial infarction using Tc-99m-labeled SDF-1 alpha. Journal of Nuclear Medicine 2008, 49(6):963-969. 10.2967/jnumed.107.050054.
167. Miyata T., Tokunaga F., Yoneya T., Yoshikawa K., Iwanaga S., Niwa M., et al. Antimicrobial peptides, isolated from horseshoe-crab hemocytes, tachyplesin-II, and polyphemusin-I and polyphemusin-II-Chemical structures and biological-activity. Journal of Biochemistry 1989, 106(4):663-668.
168. Mo W., Chen J., Patel A., Zhang L., Chau V., Li Y., et al. CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell 2013, 152(5):1077-1090.
169. Mohle R., Failenschmid C., Bautz F., Kanz L. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999, 13(12):1954-1959.
170. Mori T., Doi R., Koizumi M., Toyoda E., Ito D., Kami K., et al. CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Molecular Cancer Therapeutics 2004, 3(1):29-37.
171. Morimoto M., Mori H., Otake T., Ueba N., Kunita N., Niwa M., et al. Inhibitory effect of tachyplesin-I on the proliferation of human-immunodeficiency-virus in vitro. Chemotherapy 1991, 37(3):206-211.
172. Mosley C.A., Wilson L.J., Wiseman J.M., Skudlarek J.W., Liotta D.C. Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert Opinion on Therapeutic Patents 2009, 19(1):23-38.
173. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
174. Murakami T., Cardones A.R., Hwang S.T. Chemokine receptors and melanoma metastasis. Journal of Dermatological Science 2004, 36(2):71-78.
175. Murakami T., Maki W., Cardones A.R., Fang H., Tun Kyi A., Nestle F.O., et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Research 2002, 62(24):7328-7334.
176. Murthy S.C., Reznik S.I., Ogwudu U.C., Farver C.F., Arrossi A., Batizy L.H., et al. Winning the battle, losing the war: The noncurative "curative" resection for stage I adenocarcinoma of the lung. Annals of Thoracic Surgery 2010, 90(4):1067-1074.
177. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382(6592):635-638.
178. Nakamura T., Furunaka H., Miyata T., Tokunaga F., Muta T., Iwanaga S., et al. Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe-crab (Tachypleus tridentatus)-Isolation and chemical-structure. Journal of Biological Chemistry 1988, 263(32):16709-16713.
179. Nakashima H., Masuda M., Murakami T., Koyanagi Y., Matsumoto A., Fujii N., et al. Anti-human-immunodeficiency-virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II)-A possible inhibitor of virus-cell fusion. Antimicrobial Agents and Chemotherapy 1992, 36(6):1249-1255.
180. NCI Clinical trials (PDQ®) 2014.
181. Nervi B., Ramirez P., Rettig M.P., Uy G.L., Holt M.S., Ritchey J.K., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009, 113(24):6206-6214.
182. Nimmagadda S., Pullambhatla M., Pomper M.G. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. Journal of Nuclear Medicine 2009, 50(7):1124-1130. 10.2967/jnumed.108.061325.
183. Nimmagadda S., Pullambhatla M., Stone K., Green G., Bhujwalla Z.M., Pomper M.G. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [Cu-64]AMD3100 positron emission tomography. Cancer Research 2010, 70(10):3935-3944. 10.1158/0008-5472.can-09-4396.
184. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996, 382(6594):833-835.
185. Obermajer N., Muthuswamy R., Odunsi K., Edwards R.P., Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Research 2011, 71(24):7463-7470.
186. O'Boyle G., Swidenbank I., Marshall H., Barker C.E., Armstrong J., White S.A., et al. Inhibition of CXCR4/CXCL12 chemotaxis in melanoma by AMD11070. British Journal of Cancer 2013, 108(8):1634-1640.
187. Oh Y.S., Kim H.Y., Song I.C., Yun H.J., Jo D.Y., Kim S., et al. Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1alpha. Oncology Reports 2012, 28(6):2239-2246.
188. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Research 1999, 59(19):5002-5011.
189. Orditura M., Galizia G., Sforza V., Gambardella V., Fabozzi A., Laterza M.M., et al. Treatment of gastric cancer. World Journal of Gastroenterology 2014, 20(7):1635-1649.
190. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348.
191. Otsuka S., Klimowicz A.C., Kopciuk K., Petrillo S.K., Konno M., Hao D., et al. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. Journal of Thoracic Oncology 2011, 6(7):1169-1178.
192. Pan J., Mestas J., Burdick M.D., Phillips R.J., Thomas G.V., Reckamp K., et al. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Molecular Cancer 2006, 5:56.
193. Parmo-Cabanas M., Bartolome R.A., Wright N., Hidalgo A., Drager A.M., Teixido J. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: Role of cAMP and the actin cytoskeleton in adhesion. Experimental Cell Research 2004, 294(2):571-580.
194. Pei R.Z., Tang S.H., Ma J.X., Zhang P.S., Liu X.H., Du X.H., et al. Relationship between expression of chemokine receptor and curative effect of multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2011, 19(1):73-75.
195. Peitzsch C., Kurth I., Kunz-Schughart L., Baumann M., Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiotherapy and Oncology 2013, 108(3):378-387.
196. Peled A., Abraham M., Avivi I., Rowe J.M., Beider K., Wald H., et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clinical Cancer Research 2014, 20(2):469-479.
197. Peled A., Tavor S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics 2013, 3(1):34-39.
198. Petit I., Jin D., Rafii S. The SDF-1-CXCR4 signaling pathway: A molecular hub modulating neo-angiogenesis. Trends in Immunology 2007, 28(7):299-307.
199. Pfeiffer M., Hartmann T.N., Leick M., Catusse J., Schmitt-Graeff A., Burger M. Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer. British Journal of Cancer 2009, 100(12):1949-1956.
200. Phillips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. American Journal of Respiratory and Critical Care Medicine 2003, 167(12):1676-1686.
201. Phillips R.J., Mestas J., Gharaee-Kermani M., Burdick M.D., Sica A., Belperio J.A., et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. Journal of Biological Chemistry 2005, 280(23):22473-22481.
202. Pierce K.L., Premont R.T., Lefkowitz R.J. Seven-transmembrane receptors. Nature Reviews. Molecular Cell Biology 2002, 3(9):639-650.
203. Ping Y.F., Yao X.H., Jiang J.Y., Zhao L.T., Yu S.C., Jiang T., et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. Journal of Pathology 2011, 224(3):344-354.
204. Portella L., Vitale R., De Luca S., D'Alterio C., Ierano C., Napolitano M., et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One 2013, 8(9):e74548.
205. Porvasnik S., Sakamoto N., Kusmartsev S., Eruslanov E., Kim W.J., Cao W., et al. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009, 69(13):1460-1469.
206. Qu Q.X., Huang Q., Xu J., Duan L.T., Zhu Y.B., Zhang X.G. CD40 signal regulates CXCR4 mediating ovarian carcinoma cell migration: Implications for extrapelvic metastastic factors. Oncology Research 2013, 20(9):383-392.
207. Ratajczak M.Z., Majka M., Kucia M., Drukala J., Pietrzkowski Z., Peiper S., et al. Expression of functional CXCR4 by muscle satellite cells and secretion of SDF-1 by muscle-derived fibroblasts is associated with the presence of both muscle progenitors in bone marrow and hematopoietic stem/progenitor cells in muscles. Stem Cells 2003, 21(3):363-371.
208. Ratajczak M.Z., Zuba-Surma E., Kucia M., Reca R., Wojakowski W., Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 2006, 20(11):1915-1924.
209. Reckamp K.L., Figlin R.A., Burdick M.D., Dubinett S.M., Elashoff R.M., Strieter R.M. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer. BMC Cancer 2009, 9:213.
210. Redjal N., Chan J.A., Segal R.A., Kung A.L. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clinical Cancer Research 2006, 12(22):6765-6771.
211. Rempel S.A., Dudas S., Ge S., Gutierrez J.A. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clinical Cancer Research 2000, 6(1):102-111.
212. Rhodes L.V., Short S.P., Neel N.F., Salvo V.A., Zhu Y., Elliott S., et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research 2011, 71(2):603-613. 10.1158/0008-5472.CAN-10-3185.
213. Rubin J.B., Kung A.L., Klein R.S., Chan J.A., Sun Y., Schmidt K., et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(23):13513-13518.
214. Saini V., Marchese A., Majetschak M. CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. Journal of Biological Chemistry 2010, 285(20):15566-15576.
215. Saintigny P., Burger J.A. Recent advances in non-small cell lung cancer biology and clinical management. Discovery Medicine 2012, 13(71):287-297.
216. Salcedo R., Wasserman K., Young H.A., Grimm M.C., Howard O.M., Anver M.R., et al. Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neovascularization induced by stromal-derived factor-1alpha. American Journal of Pathology 1999, 154(4):1125-1135.
217. Salvucci O., Bouchard A., Baccarelli A., Deschenes J., Sauter G., Simon R., et al. The role of CXCR4 receptor expression in breast cancer: A large tissue microarray study. Breast Cancer Research and Treatment 2006, 97(3):275-283.
218. Sasaki K., Natsugoe S., Ishigami S., Matsumoto M., Okumura H., Setoyama T., et al. Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer. Journal of Surgical Oncology 2008, 97(5):433-438.
219. Sasaki K., Natsugoe S., Ishigami S., Matsumoto M., Okumura H., Setoyama T., et al. Expression of CXCL12 and its receptor CXCR4 in esophageal squamous cell carcinoma. Oncology Reports 2009, 21(1):65-71.
220. Scala S., Ottaiano A., Ascierto P.A., Cavalli M., Simeone E., Giuliano P., et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clinical Cancer Research 2005, 11(5):1835-1841.
221. Schabath R., Muller G., Schubel A., Kremmer E., Lipp M., Forster R. The murine chemokine receptor CXCR4 is tightly regulated during T cell development and activation. Journal of Leukocyte Biology 1999, 66(6):996-1004.
222. Schimanski C.C., Bahre R., Gockel I., Muller A., Frerichs K., Horner V., et al. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. British Journal of Cancer 2006, 95(2):210-217.
223. Schimanski C.C., Schwald S., Simiantonaki N., Jayasinghe C., Gonner U., Wilsberg V., et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clinical Cancer Research 2005, 11(5):1743-1750.
224. Schmitt S., Weinhold N., Dembowsky K., Neben K., Witzens-Harig M., Braun M., et al. First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). Blood 2010, 116(21):359-360.
225. Schober A., Zernecke A. Chemokines in vascular remodeling. Thrombosis & Haemostasis 2007, 97(5):730-737.
226. Schuller U., Koch A., Hartmann W., Garre M.L., Goodyer C.G., Cama A., et al. Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas. International Journal of Cancer 2005, 117(1):82-89.
227. Sehgal A., Keener C., Boynton A.L., Warrick J., Murphy G.P. CXCR-4, a chemokine receptor, is overexpressed in and required for proliferation of glioblastoma tumor cells. Journal of Surgical Oncology 1998, 69(2):99-104.
228. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine 1999, 5(6):662-668.
229. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012, 62(1):10-29.
230. Singh S., Srivastava S.K., Bhardwaj A., Owen L.B., Singh A.P. CXCR4/CXCL12 signalling axis confers gemcitabine resistance to pancreatic cancer cells: A novel target for therapy. British Journal of Cancer 2010, 103(11):1671-1679.
231. Sison E.A., McIntyre E., Magoon D., Brown P. Dynamic chemotherapy-induced upregulation of CXCR4 expression: A mechanism of therapeutic resistance in pediatric AML. Molecular Cancer Research 2013, 11(9):1004-1016.
232. Smith J.R., Falkenhagen K.M., Coupland S.E., Chipps T.J., Rosenbaum J.T., Braziel R.M. Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. American Journal of Clinical Pathology 2007, 127(4):633-641.
233. Smith M.C., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Research 2004, 64(23):8604-8612.
234. Smith H., Whittall C., Weksler B., Middleton J. Chemokines stimulate bidirectional migration of human mesenchymal stem cells across bone marrow endothelial cells. Stem Cells and Development 2012, 21(3):476-486.
235. Spano J.P., Andre F., Morat L., Sabatier L., Besse B., Combadiere C., et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: Pattern of expression and correlation with outcome. Annals of Oncology 2004, 15(4):613-617.
236. Spoo A.C., Lubbert M., Wierda W.G., Burger J.A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 2007, 109(2):786-791.
237. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425(6955):307-311.
238. Steinberg M., Silva M. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clinical Therapeutics 2010, 32(5):821-843.
239. Stessman H.A., Mansoor A., Zhan F., Janz S., Linden M.A., Baughn L.B., et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia 2013, 27(10):2075-2077.
240. Su L., Zhang J., Xu H., Wang Y., Chu Y., Liu R., et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clinical Cancer Research 2005, 11(23):8273-8280.
241. Sun X., Cheng G., Hao M., Zheng J., Zhou X., Zhang J., et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer and Metastasis Reviews 2010, 29(4):709-722.
242. Sun X., Cheng G., Hao M., Zheng J., Zhou X., Zhang J., et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression (vol 29, pg 709, 2010). Cancer and Metastasis Reviews 2011, 30(2):269-270. 10.1007/s10555-010-9266-8.
243. Sun Y.X., Schneider A., Jung Y., Wang J., Dai J., Wang J., et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. Journal of Bone and Mineral Research 2005, 20(2):318-329.
244. Sun Y.X., Wang J., Shelburne C.E., Lopatin D.E., Chinnaiyan A.M., Rubin M.A., et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. Journal of Cellular Biochemistry 2003, 89(3):462-473.
245. Taichman R.S., Cooper C., Keller E.T., Pienta K.J., Taichman N.S., McCauley L.K. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Research 2002, 62(6):1832-1837.
246. Tamamura H., Arakaki R., Funakoshi H., Imai M., Otaka A., Ibuka T., et al. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr(5,12), Lys(7)]-polyphemusin II). Bioorganic & Medicinal Chemistry 1998, 6(2):231-238. 10.1016/s0968-0896(97)10037-2.
247. Tamamura H., Hiramatsu K., Mizumoto M., Ueda S., Kusano S., Terakubo S., et al. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists. Organic & Biomolecular Chemistry 2003, 1(21):3663-3669.
248. Tamamura H., Hori A., Kanzaki N., Hiramatsu K., Mizumoto M., Nakashima H., et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Letters 2003, 550(1-3):79-83. 10.1016/s0014-5793(03)00824-x.
249. Tamamura H., Omagari A., Oishi S., Kanamoto T., Yamamoto N., Peiper S.C., et al. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorganic & Medicinal Chemistry Letters 2000, 10(23):2633-2637. 10.1016/s0960-894x(00)00535-7.
250. Tamamura H., Xu Y.O., Hattori T., Zhang X.Y., Arakaki R., Kanbara K., et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: A strong anti-HIV peptide T140. Biochemical and Biophysical Research Communications 1998, 253(3):877-882. 10.1006/bbrc.1998.9871.
251. Teicher B.A. Antiangiogenic agents and targets: A perspective. Biochemical Pharmacology 2011, 81(1):6-12.
252. Thoma G., Streiff M.B., Kovarik J., Glickman F., Wagner T., Beerli C., et al. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. Journal of Medicinal Chemistry 2008, 51(24):7915-7920. 10.1021/jm801065q.
253. Triano L.R., Deshpande H., Gettinger S.N. Management of patients with advanced non-small cell lung cancer: Current and emerging options. Drugs 2010, 70(2):167-179.
254. Tripathi A., Saini V., Marchese A., Volkman B.F., Tang W.J., Majetschak M. Modulation of the CXC chemokine receptor 4 agonist activity of ubiquitin through C-terminal protein modification. Biochemistry 2013, 52(24):4184-4192.
255. Vagima Y., Lapid K., Kollet O., Goichberg P., Alon R., Lapidot T. Pathways implicated in stem cell migration: The SDF-1/CXCR4 axis. Methods in Molecular Biology 2011, 750:277-289.
256. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Letters 2008, 267(2):226-244.
257. Vanharanta S., Shu W., Brenet F., Hakimi A.A., Heguy A., Viale A., et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nature Medicine 2013, 19(1):50-56.
258. Vater A., Sahlmann J., Kroger N., Zollner S., Lioznov M., Maasch C., et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clinical Pharmacology and Therapeutics 2013, 94(1):150-157.
259. Vila-Coro A.J., Rodriguez-Frade J.M., Martin De Ana A., Moreno-Ortiz M.C., Martinez A.C., Mellado M. The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB Journal 1999, 13(13):1699-1710.
260. Viola A., Luster A.D. Chemokines and their receptors: Drug targets in immunity and inflammation. Annual Review of Pharmacology and Toxicology 2008, 48:171-197.
261. Vlahakis S.R., Villasis-Keever A., Gomez T., Vanegas M., Vlahakis N., Paya C.V. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. Journal of Immunology 2002, 169(10):5546-5554.
262. Wagner P.L., Hyjek E., Vazquez M.F., Meherally D., Liu Y.F., Chadwick P.A., et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: Association with metastasis and survival. Journal of Thoracic and Cardiovascular Surgery 2009, 137(3):615-621.
263. Waki M., Waki K., Miyamoto K., Matsumoto A., Tamamura H., Fujii N., et al. Molecular size of an anti-HIV peptide, T22, can be reduced without loss of the activity. Chemistry Letters 1996, 25(7):571-572. 10.1246/cl.1996.571.
264. Wald O., Izhar U., Amir G., Avniel S., Bar-Shavit Y., Wald H., et al. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma. Journal of Immunology 2006, 177(10):6983-6990.
265. Wang L., Huang T., Chen W., Gao X., Zhou T., Wu Z., et al. Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells. Oncology Reports 2012, 28(6):2043-2048.
266. Wang D.F., Lou N., Qiu M.Z., Lin Y.B., Liang Y. Effects of CXCR4 gene silencing by lentivirus shRNA on proliferation of the EC9706 human esophageal carcinoma cell line. Tumour Biology 2013, 34(5):2951-2959.
267. Wang J.F., Park I.W., Groopman J.E. Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: Roles of phosphoinositide-3 kinase and protein kinase C. Blood 2000, 95(8):2505-2513.
268. Wang J., Wang J., Sun Y., Song W., Nor J.E., Wang C.Y., et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cellular Signalling 2005, 17(12):1578-1592.
269. Wang L., Wang L., Yang B., Yang Q., Qiao S., Wang Y., et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clinical & Experimental Metastasis 2009, 26(8):1049-1054.
270. Ward S.G. T lymphocytes on the move: Chemokines, PI 3-kinase and beyond. Trends in Immunology 2006, 27(2):80-87.
271. Wegner S.A., Ehrenberg P.K., Chang G., Dayhoff D.E., Sleeker A.L., Michael N.L. Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. Journal of Biological Chemistry 1998, 273(8):4754-4760.
272. WHO Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 2012.
273. WHO Breast cancer: Prevention and control 2014.
274. WHO Cancer (Fact sheet No. 297) 2014.
275. Woerner B.M., Warrington N.M., Kung A.L., Perry A., Rubin J.B. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Research 2005, 65(24):11392-11399.
276. Wong D., Korz W. Translating an antagonist of chemokine receptor CXCR4: From bench to bedside. Clinical Cancer Research 2008, 14(24):7975-7980.
277. Wu B., Chien E.Y.T., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330(6007):1066-1071. 10.1126/science.1194396.
278. Xiang Z.L., Zeng Z.C., Tang Z.Y., Fan J., Zhuang P.Y., Liang Y., et al. Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases and poor survival. BMC Cancer 2009, 9:176.
279. Xu T.P., Shen H., Liu L.X., Shu Y.Q. The impact of chemokine receptor CXCR4 on breast cancer prognosis: A meta-analysis. Cancer Epidemiology 2013, 37(5):725-731.
280. Xue B., Wu W., Huang K., Xie T., Xu X., Zhang H., et al. Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by alphavbeta6 integrin-mediated signaling in ovarian cancer. Molecular and Cellular Biochemistry 2013, 380(1-2):177-184.
281. Yasumoto K., Koizumi K., Kawashima A., Saitoh Y., Arita Y., Shinohara K., et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Research 2006, 66(4):2181-2187.
282. Ying J., Xu Q., Zhang G., Liu B., Zhu L. The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis. Medical Oncology 2012, 29(3):1716-1722.
283. Yu L., Cecil J., Peng S.B., Schrementi J., Kovacevic S., Paul D., et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene 2006, 374:174-179.
284. Yu L., Hales C.A. Effect of chemokine receptor CXCR4 on hypoxia-induced pulmonary hypertension and vascular remodeling in rats. Respiratory Research 2011, 12:21.
285. Zabel B.A., Agace W.W., Campbell J.J., Heath H.M., Parent D., Roberts A.I., et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. Journal of Experimental Medicine 1999, 190(9):1241-1256.
286. Zagzag D., Esencay M., Mendez O., Yee H., Smirnova I., Huang Y., et al. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: One plausible explanation of Scherer's structures. American Journal of Pathology 2008, 173(2):545-560. 10.2353/ajpath.2008.071197.
287. Zagzag D., Krishnamachary B., Yee H., Okuyama H., Chiriboga L., Ali M.A., et al. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Research 2005, 65(14):6178-6188.
288. Zagzag D., Lukyanov Y., Lan L., Ali M.A., Esencay M., Mendez O., et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: Implications for angiogenesis and glioma cell invasion. Laboratory Investigation 2006, 86(12):1221-1232.
289. Zeelenberg I.S., Ruuls-Van Stalle L., Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Research 2003, 63(13):3833-3839.
290. Zeng Z., Shi Y.X., Samudio I.J., Wang R.Y., Ling X., Frolova O., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113(24):6215-6224.
291. Zhang X.-X., Sun Z., Guo J., Wang Z., Wu C., Niu G., et al. Comparison of F-18-labeled CXCR4 antagonist peptides for PET imaging of CXCR4 expression. Molecular Imaging and Biology 2013, 15(6):758-767. 10.1007/s11307-013-0640-0.
292. Zhang J.M., Tian J.H., Li T.R., Guo H.Y., Shen L. Tc-99m-AMD3100: A novel potential receptor-targeting radiopharmaceutical for tumor imaging. Chinese Chemical Letters 2010, 21(4):461-463. 10.1016/j.cclet.2009.12.018.
293. Zhang X.F., Wang J.F., Matczak E., Proper J.A., Groopman J.E. Janus kinase 2 is involved in stromal cell-derived factor-1alpha-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood 2001, 97(11):3342-3348.
294. Zhong C., Wang J., Li B., Xiang H., Ultsch M., Coons M., et al. Development and preclinical characterization of a humanized antibody targeting CXCL12. Clinical Cancer Research 2013, 19(16):4433-4445. 10.1158/1078-0432.ccr-13-0943.
295. Zlotnik A. New insights on the role of CXCR4 in cancer metastasis. Journal of Pathology 2008, 215(3):211-213.
296. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393(6685):595-599.